What's Wrong With Acellular Pertussis Vaccines?

Clinical Therapeutics

Volumn 35, Issue 2, 2013, Pages 115-118

  Wiedermann, Bernhard L ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; BORDETELLA; BORDETELLA HOLMESII; BORDETELLA PERTUSSIS; CLINICAL PROTOCOL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNIZATION; INCIDENCE; INFECTION PREVENTION; PERTUSSIS; POLYMERASE CHAIN REACTION;

DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; PERTUSSIS VACCINE; UNITED STATES; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84873599392     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.01.006     Document Type: Article

References (24)

1. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1-25. Centers for Disease Control and Prevention.
2. Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 2013, 61:ND719-ND732. Centers for Disease Control and Prevention, Accessed January 23, 2013. http://www.cdc.gov/mmwr/PDF/wk/mm6152md.pdf.
3. Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep 2012, 61:517-522. Centers for Disease Control and Prevention.
4. Gustafsson L., Hessel L., Storsaeter J., et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006, 118:978-984.
5. Zepp F., Heininger U., Mertsola J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11:557-570.
6. Lavine J.S., Bjornstad O.N., Freiesleben de Blasio B., et al. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine 2012, 30:544-551.
7. Chan M.H., Ma L., Sidelinger D., et al. The California pertussis epidemic in 2010: a review of 986 pediatric case reports from San Diego County. J Pediatr Infect Dis Society 2012, 1:47-54.
8. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
9. Klein N.P., Bartlett J., Rowhani-Rahbar A., et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019.
10. Misegades L.K., Winter K., Harriman K., et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012, 308:2126-2132.
11. Cherry J.D. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
12. Cherry J.D. Why do pertussis vaccines fail?. Pediatrics 2012, 129:968-970.
13. Patriarca P.A., Biellik R.J., Sanden G., et al. Sensitivity and specificity of clinical case definitions for pertussis. Am J Public Health 1988, 78:833-836.
14. Heininger U., Cherry J.D., Eckhardt T., et al. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J 1993, 12:504-509.
15. Cherry J.D., Heininger U., Stehr K., et al. The effect of investigator compliance (observer bias) on calculated efficacy in a vaccine trial. Pediatrics 1998, 102:909-912.
16. Rodgers L., Martin S.W., Cohn A., et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis-Ohio, 2010-2011. Clin Infect Dis 2013, 56:322-331.
17. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ 1988, 296:612-614.
18. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988, 1:955-960. Ad Hoc Group for the Study of Pertussis Vaccines.
19. Greco D., Salmaso S., Mastrantonio P., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996, 334:341-348.
20. Gustafsson L., Hallander H.O., Olin P., et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
21. Clark T.A. Responding to pertussis. J Pediatr 2012, 161:980-982.
22. Winter K., Harriman K., Zipprich J., et al. California pertussis epidemic, 2010. J Pediatr 2012, 161:1091-1096.
23. Cherry J.D., Tan T., von Konig C.H., et al. Clinical definitions of pertussis: summary of a global pertussis initiative roundtable meeting, February 2011. Clin Infect Dis 2012, 54:1756-1764.
24. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or antibipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1424-1426. Centers for Disease Control and Prevention (CDC).